Premium
Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies
Author(s) -
Svrcek Magali,
Cros Jérôme,
Maréchal Raphael,
Bachet JeanBaptiste,
Fléjou JeanFrançois,
Demetter Pieter
Publication year - 2015
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.12577
Subject(s) - pancreatic ductal adenocarcinoma , rabbit (cipher) , antibody , pancreatic carcinoma , adenocarcinoma , nucleoside , transporter , chemistry , pancreatic cancer , biology , medicine , pathology , cancer , biochemistry , immunology , gene , statistics , mathematics
Aims The human equilibrative nucleoside transporter 1 (h ENT 1) expression level in pancreatic ductal adenocarcinoma (PDAC) may predict survival in gemcitabine‐treated patients after resection. These results have been obtained with a murine anti‐h ENT 1 antibody (10D7G2) that is not commercially available. Another antibody, which is rabbit‐derived (SP120), appears to have no predictive value in local, advanced or metastatic PDAC. We aimed to study whether the two antibodies are equivalent. Methods and results We compared h ENT 1 expression with both antibodies in resected PDAC. The results were correlated with overall survival (OS) following gemcitabine treatment. Tissues from two sets of patients ( n = 147 each) were stained with SP120 by the use of different equipment, with an amplification technique being used for set 2. The rate of ‘h ENT 1 high' cases was lower with SP120 (set 1, 7% versus 48%; set 2, 11% versus 38%). With the amplification technique, the rate of h ENT 1 high cases was globally similar between both antibodies. However, concordance between the antibodies was found in only 50% of cases. High h ENT 1 expression was predictive of OS only with 10D7G2 (hazard ratio 0.49; 95% confidence interval 0.24–0.98; P = 0.045). Conclusions The two antibodies are not equivalent. Further prospective studies seem to be warranted before h ENT 1 testing for PDAC is used in daily practise.